ILARIS 150 MG
CANAKINUMAB : 150 MG · DIN 02460351 · NOVARTIS PHARMACEUTICALS CANADA INC
Health Canada status: MARKETED
What is ILARIS?
ILARIS 150 MG contains CANAKINUMAB : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02460351, held by NOVARTIS PHARMACEUTICALS CANADA INC, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 22-Aug-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ILARIS used for?
ILARIS (canakinumab) is an interleukin-1 beta (IL-1β) inhibitor indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), Tumor Necrosis Factor receptor Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD), Familial Mediterranean Fever (FMF), and Still’s disease (Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still’s Disease (AOSD)).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02460351 |
|---|---|
| Brand name | ILARIS |
| Generic / active ingredient | CANAKINUMAB : 150 MG |
| Manufacturer | NOVARTIS PHARMACEUTICALS CANADA INC |
| Strength | 150 MG |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Prescription |
| ATC code | L04AC08 CANAKINUMAB |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 22-Aug-2017 |
How is it stored and handled?
null
How is it supplied?
Ilaris is supplied in sterile, single-use, colorless 2 mL glass vial closed with a grey stopper, covered with an aluminium crimp seal with plastic flip-off cap. Each vial contains 150 mg/ 1 mL of canakinumab as a clear to opalescent, colorless to slightly brownish yellow solution. A volume of up to 1.0 mL can be withdrawn, which is designed to deliver 150 mg for subcutaneous administration only.
What can be used instead?
Other Canadian products sharing ATC code L04AC08 CANAKINUMAB. 1 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ILARIS | 150 MG | POWDER FOR SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | CANCELLED POST MARKET | DIN 02344939 |
Who else supplies CANAKINUMAB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CANAKINUMAB appears in 10 registered pack listings across 9 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.